Drugs / YL205
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06459973 | Jun 2024 → Jul 2027 expected | cancer | MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YL205 | “YL205 is provided in the form of lyophilized powder under a strength of 160 mg/vial.” NCT06459973 ↗ |
| Route | Intravenous | “treated with YL205 via intravenous (IV) infusion” NCT06459973 ↗ |